Annual trends in use of periconceptional folic acid and birth prevalence of major congenital malformations

Current Drug Safety

Volumn 8, Issue 3, 2013, Pages 153-161

  Richard Tremblay, Audrey Ann ^a,b   Sheehy, Odile ^b   Bérard, Anick ^a,b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITY OF MONTREAL   (Canada)

Author keywords

Birth defects; Folic acid; Major congenital malformations; Population based study; Pregnancy

Indexed keywords

ANTICONVULSIVE AGENT; FOLIC ACID;

ARTICLE; BIRTH; CONCEPTION; CONGENITAL MALFORMATION; DATA BASE; DELIVERY; DIAGNOSTIC TEST; EPILEPSY; HUMAN; MEDICAL INFORMATION; MUSCULOSKELETAL DISEASE; NEURAL TUBE DEFECT; PRIORITY JOURNAL;

ADOLESCENT; ADULT; CONGENITAL ABNORMALITIES; DATABASES, FACTUAL; FEMALE; FOLIC ACID; HEART DEFECTS, CONGENITAL; HUMANS; INFANT, NEWBORN; MIDDLE AGED; MUSCULOSKELETAL ABNORMALITIES; NERVOUS SYSTEM MALFORMATIONS; PREGNANCY; PREGNANCY OUTCOME; PREVALENCE; QUEBEC; REGISTRIES; TREATMENT OUTCOME; VITAMIN B COMPLEX; YOUNG ADULT;

EID: 84882802642     PISSN: 15748863     EISSN: None     Source Type: Journal    
DOI: 10.2174/15748863113089990034     Document Type: Article

References (45)

1. Rynn L, Cragan J, Correa A. Centers for Disease Control and Prevention. Update on overall prevalence of major birth defects-Atlanta, Georgia, 1978-2005. MMWR Morb Mortal Wkly Rep 2008; 57(1): 1-5.
2. Public Health Agency of Canada. Canadian Perinatal Health Report, 2008 Edition. Ottawa: Minister of Health, 2008.
3. Kochanek KD, Kirmeyer SE, Martin JA, Strobino DM, Guyer B. Annual summary of vital statistics: 2009. Pediatrics 2012; 129(2): 338-348.
4. MRC Vitamin Study Research Group. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. Lancet 1991; 338(8760): 131-137.
5. Czeizel AE. Prevention of congenital abnormalities by periconcept-ional multivitamin supplementation. BMJ 1993; 306(6893): 1645-1658.
6. Berry RJ, Li Z, Erickson JD, et al. Prevention of neural-tube defects with folic acid in China. China-U.S. Collaborative Project for Neural Tube Defect Prevention. N Engl J Med 1999; 341(20): 1485-1490.
7. Kirke PN, Daly LE, Elwood JH. A randomised trial of low dose folic acid to prevent neural tube defects. The Irish Vitamin Study Group. Arch Dis Child 1992; 67(12): 1442-1446.
8. De Wals P, Tairou F, Van Allen MI, et al. Reduction in neural-tube defects after folic acid fortification in Canada. N Engl J Med 2007; 357(2): 135-142.
9. Mersereau P, Kilker K, Carter H, et al. Centers for Disease Control and prevention. Spina bifida and anencephaly before and after folic acid mandate--United States, 1995-1996 and 1999-2000. MMWR Morb Mortal Wkly Rep 2004; 53(17): 362-365.
10. Czeizel AE. Periconceptional folic acid containing multivitamin supplementation. Eur J Obstet Gynecol Reprod Biol 1998; 78(2): 151-161.
11. Botto LD, Mulinare J, Erickson JD. Occurrence of congenital heart defects in relation to maternal mulitivitamin use. Am J Epidemiol 2000; 151(9): 878-884.
12. Hernandez-Diaz S, Werler MM, Walker AM, Mitchell AA. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med 2000; 343(22): 1608-1614.
13. Shaw GM, O'Malley CD, Wasserman CR, Tolarova MM, Lammer EJ. Maternal periconceptional use of multivitamins and reduced risk for conotruncal heart defects and limb deficiencies among offspring. Am J Med Genet 1995; 59(4): 536-545.
14. Scanlon KS, Ferencz C, Loffredo CA, et al. Preconceptional folate intake and malformations of the cardiac outflow tract. Baltimore-Washington Infant Study Group. Epidemiology 1998; 9(1): 95-98.
15. Itikala PR, Watkins ML, Mulinare J, Moore CA, Liu Y. Maternal multivitamin use and orofacial clefts in offspring. Teratology 2001; 63(2): 79-86.
16. Werler MM, Hayes C, Louik C, Shapiro S, Mitchell AA. Multivit-amin supplementation and risk of birth defects. Am J Epidemiol 1999; 150(7): 675-682.
17. Houk N, Oakley P, Erickson JD, Mulinare J, James M. Centers for Disease Control and Prevention. Recommendations for the use of folic acid to reduce the number of cases of spina bifida and other neural tube defects. MMWR Recomm Rep 1992; 41(RR-14): 1-7.
18. Van Allen MI, Fraser FC, Dallaire L, et al. Recommendations on the use of folic acid supplementation to prevent the recurrence of neural tube defects. Clinical Teratology Committee, Canadian College of Medical Geneticists. CMAJ 1993; 149(9): 1239-1243.
19. Wilson RD, Davies G, Désilets V, et al. Genetics Committee and Executive and Council of the Society of Obstetricians and Gynaecologists of Canada. The use of folic acid for the prevention of neural tube defects and other congenital anomalies. J Obstet Gynaecol Can 2003; 25(11): 959-973.
20. Wilson RD, Johnson JA, Wyatt P, et al. Genetics Committee of the Society of Obstetricians and Gynaecologists of Canada and The Motherrisk Program. Pre-conceptional vitamin/folic acid supplementation 2007: the use of folic acid in combination with a multivitamin supplement for the prevention of neural tube defects and other congenital anomalies. J Obstet Gynaecol Can 2007; 29(12): 1003-1026.
21. Richard-Tremblay AA, Sheehy O, Audibert F, Ferreira E, Berard A. Concordance between periconceptional folic acid supplementation and Canadian Clinical Guidelines. J Popul Ther Clin Pharmacol 2012; 19(2): e150-e159.
22. World Health Organisation. International Statistical Classification of Diseases and Related Health Problems, 9th Revision (ICD-9). 9th revision ed1999.
23. Régie de l'assurance maladie du Québec. Présentation de la Régie de l'assurance maladie du Québec. Québec; 2010. p. 1-19.
24. th, 2011]; Available from: http://www.ramq.gouv.qc.ca/fr/statistiques/index.shtml
25. World Health Organisation. International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10).
26. Vilain A, Otis S, Forget A, Blais L. Agreement between administrative databases and medical charts for pregnancy-related variables among asthmatic women. Pharmacoepidemiol Drug Saf 2008; 17(4): 345-353.
27. Berard A, Nakhai-Pour HR, Broy P. Antidepressant use (during pregnancy) and miscarriage. CMAJ 2010; 182(10): 1079.
28. Nakhai-Pour HR, Broy P, Sheehy O, Berard A. Use of nonaspirin nonsteroidal anti-inflammatory drugs during pregnancy and the risk of spontaneous abortion. CMAJ 2011; 183(15): 1713-1720.
29. Martel MJ, Rey E, Beauchesne MF, et al. Use of inhaled corticosteroids during pregnancy and risk of pregnancy induced hypertension: nested case-control study. BMJ 2005; 330(7485): 230.
30. Moore KL. Before we are born: essentials of embryology and birth defects. 7th ed: Philadelphia, PA: Saunders Elsevier 2008.
31. Werler MM, Ahrens KA, Bosco JLF, et al. National Birth Defects Prevention Study: Use of Antiepileptic Medications in Pregnancy in Relation to Risks of Birth Defects. Ann Epidemiol 2011; 21(11): 842-850.
32. Artama M, Auvinen A, Raudaskoski T, Isojarvi I, Isojarvi J. Antiepileptic drug use of women with epilepsy and congenital malformations in offspring. Neurology 2005; 64(11): 1874-1878.
33. Cheschier N, ACOG Committee on Practice Bulletins-Obstetrics. ACOG practice bulletin. Neural tube defects. Number 44, July 2003. (Replaces committee opinion number 252, March 2001). Int J Gynaecol Obstet 2003; 83(1): 123-133.
34. Calonge N, Petitti DB, DeWitt TG, et al. U.S. Preventive Services Task Forces. Folic acid for the prevention of neural tube defects: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2009; 150(9): 626-631.
35. Tomson T, Hiilesmaa V. Epilepsy in pregnancy. BMJ 2007; 335(7623): 769-773.
36. Fried S, Kozer E, Nulman I, Einarson TR, Koren G. Malformation rates in children of women with untreated epilepsy: a meta-analysis. Drug Saf 2004; 27(3): 197-202.
37. Van Allen MI, McCourt C, Lee NS. Preconception health: folic acid for the primary prevention of neural tube defects. A resource document for health professionals Ottawa, Ontario: Minister of Public Works and Government Services Canada; 2002.
38. Perucca E. Birth defects after prenatal exposure to antiepileptic drugs. Lancet Neurol 2005; 4(11): 781.
39. Koren G, Nava-Ocampo AA, Moretti ME, Sussman R, Nulman I. Major malformations with valproic acid. Can Fam Physician 2006; 52: 441.
40. Langlois PH, Marengo LK, Canfield MA. Time trends in the prevalence of birth defects in Texas 1999-2007: real or artifactual? Birth Defects Res A Clin Mol Teratol 2011; 91(10): 902-917.
41. Correa A, Cragan JD, Kucik JE, et al. Reporting birth defects surveillance data 1968-2003. Birth Defects Res A Clin Mol Teratol 2007; 79(2): 65-186.
42. Hung J, Lang R, Flachskampf F, et al. 3D Echocardiography: A Review of the Current Status and Future Directions. J Am Soc Echocardiogr 2007; 20(3): 213-233.
43. Tamblyn R, Lavoie G, Petrella L, Monette J. The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Quebec. J Clin Epidemiol 1995; 48(8): 999-1009.
44. Kulaga S, Berard A. Congenital malformations: agreement between diagnostic codes in an administrative database and mothers' reports. J Obstet Gynaecol Can 2010; 32(6): 549-554.
45. Berard A, Lacasse A. Validity of perinatal pharmacoepidemiologic studies using data from the RAMQ administrative database. Can J Clin Pharmacol 2009; 16(2): e360-e369.